ATR抑制剂研发困难重重，阿斯利康等大批药企已接连受挫

制药网2025-12-31

近日，阿斯利康宣布，旗下ATR抑制剂Ceralasertib在Ⅲ期临床试验中未达到主要终点。LATIFY是其一项针对Ceralasertib的Ⅲ期临床试验，此次试验旨在评估Ceralasertib联合Imfinzi(度伐利尤单抗)治疗局部晚期或转移性非小细胞肺癌(NSCLC)患者的疗效，这些患者此前曾接受免疫治疗及铂类化疗。但临床结果显示，与标准化疗药物多西他赛相比，该联合方案未能改善患者的总...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595783607?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-31 13:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2595783607","market":"hk","top_or_hot":-1,"title":"ATR抑制剂研发困难重重，阿斯利康等大批药企已接连受挫","media":"制药网","content":"<div>\n<p>近日，阿斯利康宣布，旗下ATR抑制剂Ceralasertib在Ⅲ期临床试验中未达到主要终点。LATIFY是其一项针对Ceralasertib的Ⅲ期临床试验，此次试验旨在评估Ceralasertib联合Imfinzi(度伐利尤单抗)治疗局部晚期或转移性非小细胞肺癌(NSCLC)患者的疗效，这些患者此前曾接受免疫治疗及铂类化疗。但临床结果显示，与标准化疗药物多西他赛相比，该联合方案未能改善患者的总...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231134259a48d2bdb&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ATR抑制剂研发困难重重，阿斯利康等大批药企已接连受挫</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nATR抑制剂研发困难重重，阿斯利康等大批药企已接连受挫\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-31 13:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231134259a48d2bdb&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，阿斯利康宣布，旗下ATR抑制剂Ceralasertib在Ⅲ期临床试验中未达到主要终点。LATIFY是其一项针对Ceralasertib的Ⅲ期临床试验，此次试验旨在评估Ceralasertib联合Imfinzi(度伐利尤单抗)治疗局部晚期或转移性非小细胞肺癌(NSCLC)患者的疗效，这些患者此前曾接受免疫治疗及铂类化疗。但临床结果显示，与标准化疗药物多西他赛相比，该联合方案未能改善患者的总...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231134259a48d2bdb&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231134259a48d2bdb&s=b","article_id":"2595783607","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231134259a48d2bdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2595783607","pubTimestamp":1767159710,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，阿斯利康宣布，旗下ATR抑制剂Ceralasertib在Ⅲ期临床试验中未达到主要终点。据了解，近年来ATR抑制剂研发领域已遭遇了一系列重大挫折，除了阿斯利康重磅III期临床试验失败，还有不少药企因项目停滞或合作终止退出了这一赛道的竞争。如2023年，拜耳终止了其处于I期临床阶段的ATR抑制剂Elimusertib的研发。例如复星医药在2025年12月宣布，其自主研发的口服ATR抑制剂FXS0887片已获批开展针对晚期恶性实体瘤的I期临床试验。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1593":"医美概念股","02196":"复星医药","01276":"恒瑞医药"},"translate_title":"The development of ATR inhibitors is difficult, and a large number of pharmaceutical companies such as AstraZeneca have suffered setbacks one after another","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":0.9,"01276":0.9},"content_text":"近日，阿斯利康宣布，旗下ATR抑制剂Ceralasertib在Ⅲ期临床试验中未达到主要终点。LATIFY是其一项针对Ceralasertib的Ⅲ期临床试验，此次试验旨在评估Ceralasertib联合Imfinzi(度伐利尤单抗)治疗局部晚期或转移性非小细胞肺癌(NSCLC)患者的疗效，这些患者此前曾接受免疫治疗及铂类化疗。但临床结果显示，与标准化疗药物多西他赛相比，该联合方案未能改善患者的总生存期(OS)。据了解，近年来ATR抑制剂研发领域已遭遇了一系列重大挫折，除了阿斯利康重磅III期临床试验失败，还有不少药企因项目停滞或合作终止退出了这一赛道的竞争。如2023年，拜耳终止了其处于I期临床阶段的ATR抑制剂Elimusertib的研发。德国默克则于2022年6月，因预期不佳叫停了Berzosertib联合拓扑替康治疗复发性铂耐药小细胞肺癌的全球II期试验。2024年2月，罗氏将口服ATR抑制剂Camonsertib的权益退还给了Repare Therapeutics，其理由是战略审查和外部因素变化。双方于2022年达成的该项合作涉及1.25亿美元预付款及高达12亿美元的潜在里程碑付款。业内分析认为，这些接连的失败并非偶然，它反映了药企在ATR抑制剂这一细分赛道还面临许多挑战。但值得注意的是，尽管跨国药企频频受挫，整个领域研发创新却并未停滞。据悉，国内药企仍在积极布局，试图寻找突破口。例如复星医药在2025年12月宣布，其自主研发的口服ATR抑制剂FXS0887片已获批开展针对晚期恶性实体瘤的I期临床试验。该药物剂型为片剂，用法为口服，每日一次，剂量按方案规定。本次试验主要目的为评估FXS887在晚期实体瘤患者中的安全性和耐受性，确定II期推荐剂量。英派药业的 IMP9064 是潜在中国头个具备同类最佳潜力的ATR选择性抑制剂。目前也正在通过全球I/II期试验评估其单药治疗及联合治疗用于晚期实体瘤的效果。值得一提的是，2025年9月NMPA还已批准英派药业就IMP9064(ATR抑制剂)与塞纳帕利(PARP抑制剂)联合疗法提交的新药临床试验申请(IND)。‌此外，恒瑞医药以及智康弘义、正大天晴等也均已有项目处于临床阶段。总的来说，ATR抑制剂领域的发展高度依赖于基础科学的进步和临床策略的优化。在产业发展中虽然研发挑战巨大，但鉴于其广阔的技术潜力与市场前景，未来该靶点仍是全球及中国药企在肿瘤精准治疗领域的必争之地。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595783607","isCrawlerRequest":true}